

Jin-Yuan Shih

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3762276/jin-yuan-shih-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

171
papers

8,382
citations

43
h-index

89
g-index

182
ext. papers

9,785
ext. citations

5.7
avg, IF

5.99
L-index

#	Paper	IF	Citations
171	An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100292	1.4	0
170	RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.. <i>Drug Safety</i> , 2021 , 45, 45	5.1	1
169	Subsequent Antituberculous Treatment May Not Be Mandatory Among Surgically Resected Culture-Negative Pulmonary Granulomas: A Retrospective Nationwide Multicenter Cohort Study.. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab565	1	0
168	Multi-energy level fusion for nodal metastasis classification of primary lung tumor on dual energy CT using deep learning.. <i>Computers in Biology and Medicine</i> , 2021 , 141, 105185	7	0
167	Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life. <i>Psychology and Health</i> , 2021 , 36, 1102-1114	2.9	1
166	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 841-850	4.2	1
165	Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel. <i>PLoS ONE</i> , 2021 , 16, e0248942	3.7	2
164	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. <i>Advances in Therapy</i> , 2021 , 38, 2038-2053	4.1	6
163	Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9072-9072	2.2	
162	Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer. <i>Cancer Letters</i> , 2021 , 508, 76-91	9.9	5
161	Dual energy CT image prediction on primary tumor of lung cancer for nodal metastasis using deep learning. <i>Computerized Medical Imaging and Graphics</i> , 2021 , 91, 101935	7.6	3
160	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
159	Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1. <i>Molecular Oncology</i> , 2021 , 15, 560-578	7.9	2
158	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100140	1.4	2
157	Differences in Fatty Acid Oxidation between -Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics. <i>ACS Omega</i> , 2021 , 6, 5138-5145	3.9	1
156	Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
155	Real-world insights into patients with advanced NSCLC and MET alterations. <i>Lung Cancer</i> , 2021 , 159, 96-106	5.9	0

154	Clinicopathologic Features and Response to Therapy of Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2791-2802	2.2	9
153	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021 , 156, 1-11	7.5	1
152	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100099	1.4	
151	Efficacy and Safety of Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Combined with Endobronchial Ultrasound in Peripheral Pulmonary Lesions. <i>Respiration</i> , 2021 , 100, 538-546	3.7	2
150	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020 , 25, 702-711	5.7	11
149	MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. <i>Cancer Biomarkers</i> , 2020 , 28, 351-363	3.8	8
148	Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1506-1513	3.2	1
147	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 22, 76-82	4.6	6
146	Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 145, 1-9	5.9	9
145	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , 2020 , 124, 110-122	7.5	28
144	Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. <i>Cancer Science</i> , 2020 , 111, 4510-4525	6.9	8
143	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020 , 12,	6.6	4
142	Effect of ßBlocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs. <i>Frontiers in Oncology</i> , 2020 , 10, 583529	5.3	6
141	miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 22, 471-483	10.7	9
140	Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2 Mutation.. <i>JCO Precision Oncology</i> , 2020 , 4, 912-915	3.6	
139	Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma. <i>EBioMedicine</i> , 2020 , 57, 102846	8.8	6
138	Successful Management of a -Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors. <i>OncoTargets and Therapy</i> , 2020 , 13, 10123-10127	4.4	1
137	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 17588359209461564	5.4	3

136	An Observational Study of Acquired T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. <i>Frontiers in Oncology</i> , 2020 , 10, 1481	5.3	7
135	Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. <i>Theranostics</i> , 2020 , 10, 10925-10939	12.1	9
134	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. <i>Frontiers in Oncology</i> , 2020 , 10, 590356	5.3	1
133	Primary resistance to osimertinib despite acquired. <i>Respirology Case Reports</i> , 2020 , 8, e00532	0.9	3
132	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. <i>European Journal of Cancer</i> , 2019 , 119, 77-86	7.5	12
131	Validation of Immunohistochemistry for the Detection of V600E-Mutated Lung Adenocarcinomas. <i>Cancers</i> , 2019 , 11,	6.6	9
130	Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. <i>International Journal of Cancer</i> , 2019 , 145, 1609-1624	7.5	19
129	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. <i>Lung Cancer</i> , 2019 , 133, 103-109	5.9	17
128	Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2019 , 15, 115-118	3.1	1
127	A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor. <i>Respirology Case Reports</i> , 2019 , 7, e00425	0.9	2
126	MicroRNA in Lung Cancer Metastasis. <i>Cancers</i> , 2019 , 11,	6.6	39
125	Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. <i>Oncogene</i> , 2019 , 38, 455-468	9.2	89
124	Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2019 , 20, e620-e630	4.9	23
123	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019 , 117, 107-115	7.5	18
122	The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 880	5.3	8
121	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1655-1669	21.7	215
120	Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. <i>BMC Cancer</i> , 2019 , 19, 1006	4.8	9
119	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3000-3000	2.2	18

118	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9081-9081	2.2	9
117	The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on	0.1	
116	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. <i>Oncologist</i> , 2019 , 24, e1417-e1423	5.7	13
115	Retraction: Knockdown of Contactin-1 Expression Suppresses Invasion and Metastasis of Lung Adenocarcinoma. <i>Cancer Research</i> , 2019 , 79, 3793	10.1	
114	IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
113	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019 , 144, 2887-2896	7.5	32
112	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018 , 19, e361-e372	4.9	14
111	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018 , 17, 38	42.1	253
110	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018 , 78, 3350-3362	10.1	23
109	The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2018 , 8, 5837	4.9	10
108	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <i>Lung Cancer</i> , 2018 , 120, 62-69	5.9	18
107	Response to Stephane Renaud et al. <i>Radiotherapy and Oncology</i> , 2018 , 129, 188-189	5.3	
106	Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. <i>Lung Cancer</i> , 2018 , 118, 90-96	5.9	6
105	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 326-331	3.2	7
104	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2018 , 126, 368-374	5.3	17
103	Miliary Pulmonary Nodules: An Unusual Presentation of Leptospirosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1334-1335	10.2	
102	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018 , 9, 1813-1820	4.5	34
101	Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. <i>Neoplasia</i> , 2018 , 20, 838-847	6.4	15

100	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 513-521	5	9
99	Prognostic factors of afatinib as a first-line therapy for advanced mutation-positive lung adenocarcinoma: a real-world, large cohort study. <i>Oncotarget</i> , 2018 , 9, 23749-23760	3.3	14
98	High Expression of FOXC1 in EGFR-TKI Resistant Non-Small Cell Lung Cancer. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO4-6-8	0	
97	Role of AKT3 in EGFR-TKI resistance of non-small cell lung cancer. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO4-6-13	0	
96	Regulation EGFR-TKI resistance by Long Noncoding RNA Clusterin in Non-Small Cell Lung Cancer. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO4-6-12	0	
95	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 107-116	35.1	86
94	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018 , 4, 1-12	2.6	6
93	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1897-1905	8.9	45
92	Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?. <i>European Journal of Cancer</i> , 2018 , 103, 32-40	7.5	9
91	Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas. <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 373-381	5	13
90	Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain After Sequential Use of ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e49-e51	8.9	9
89	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. <i>Cancer Letters</i> , 2017 , 402, 190-202	9.9	37
88	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017 , 22, 1075-1083	5.7	19
87	Significant Clinical Factors Associated with Long-term Mortality in Critical Cancer Patients Requiring Prolonged Mechanical Ventilation. <i>Scientific Reports</i> , 2017 , 7, 2148	4.9	6
86	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. <i>Lung Cancer</i> , 2017 , 103, 82-89	5.9	31
85	Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 567-572	8.9	139
84	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 324-332.e1	4.9	26
83	Expression of Notch Gene and Its Impact on Survival of Patients with Resectable Non-small Cell Lung Cancer. <i>Journal of Cancer</i> , 2017 , 8, 1292-1300	4.5	25

82	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1403-1410	2.2	198
81	Lung adenocarcinoma patients of young age have lower mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. <i>ERJ Open Research</i> , 2017 , 3,	3.5	21
80	Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e94-e95	8.9	1
79	Real-world experience of afatinib as a first-line therapy for advanced mutation-positive lung adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 90430-90443	3.3	46
78	Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit. <i>Journal of Cancer</i> , 2017 , 8, 1995-2003	4.5	13
77	Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. <i>Oncotarget</i> , 2017 , 8, 61901-61916	3.3	9
76	IGFBP-7 to confer resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20572-e20572	2.2	
75	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. <i>Scientific Reports</i> , 2016 , 6, 35249	4.9	24
74	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1140-52	8.9	46
73	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016 , 94, 46-53	5.9	48
72	Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9014-9014	2.2	5
71	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016 , 7, 12404-13	3.3	165
70	East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). <i>Cancer Research and Treatment</i> , 2016 , 48, 1177-1186	5.2	13
69	Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016 , 9, 6137-6145	4.4	27
68	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016 , 17, e77-e94	4.9	23
67	Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma. <i>JAMA Oncology</i> , 2016 , 2, 826-8	13.4	16
66	DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers. <i>Clinical Cancer Research</i> , 2015 , 21, 428-38	12.9	30
65	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 274-90	5.4	18

64	Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 38-45	3.6	25
63	Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e95-e96	8.9	16
62	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. <i>Scientific Reports</i> , 2015 , 5, 13574	4.9	28
61	Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e58-60	8.9	12
60	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. <i>Oncotarget</i> , 2015 , 6, 10415-31	3.3	49
59	Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. <i>PLoS ONE</i> , 2015 , 10, e0120852	3.7	58
58	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. <i>Lung Cancer</i> , 2015 , 88, 208-14	5.9	41
57	Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015 , 16, e131-40	4.9	7
56	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 793-799	8.9	139
55	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. <i>PLoS ONE</i> , 2015 , 10, e0145936	3.7	15
54	Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. <i>Oncotarget</i> , 2015 , 6, 12481-92	3.3	9
53	Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19061-e19061	2.2	
52	Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial). <i>Journal of Clinical Oncology</i> , 2015 , 33, 8043-8043	2.2	
51	Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas \geq 2 cm in maximal dimension. <i>Journal of Surgical Oncology</i> , 2014 , 110, 99-106	2.8	25
50	Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. <i>Medical Oncology</i> , 2014 , 31, 34	3.7	17
49	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1171-9	8.9	57
48	A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19013-e19013	2.2	1
47	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. <i>Lung Cancer</i> , 2013 , 82, 420-5	5.9	32

46	Survival of lung adenocarcinoma patients with malignant pleural effusion. <i>European Respiratory Journal</i> , 2013 , 41, 1409-18	13.6	68
45	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Letters</i> , 2013 , 328, 144-51	9.9	106
44	BIM deletion polymorphism to predict systemic treatment outcome in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8055-8055	2.2	
43	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 98-104	8.9	76
42	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 539-48	21.7	331
41	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 433-40	2.2	420
40	Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 973-81	8.9	49
39	Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 143-50	8.9	45
38	Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. <i>Chest</i> , 2012 , 141, 420-428	5.3	34
37	Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. <i>Lung Cancer</i> , 2011 , 72, 205-12	5.9	62
36	Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. <i>Lung Cancer</i> , 2011 , 74, 132-8	5.9	94
35	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <i>Lung Cancer</i> , 2011 , 72, 333-9	5.9	37
34	Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. <i>PLoS ONE</i> , 2011 , 6, e23303	3.7	38
33	The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 378-83	8.9	18
32	Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 195-8	8.9	69
31	Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. <i>Cancer Science</i> , 2011 , 102, 282-7	6.9	53
30	EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2952-60	3.1	43
29	Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 1071-9	10.2	129

28	The EMT regulator slug and lung carcinogenesis. <i>Carcinogenesis</i> , 2011 , 32, 1299-304	4.6	240
27	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3812-21	12.9	336
26	The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancers</i> , 2011 , 3, 2667-78	6.6	5
25	Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations. <i>Journal of Clinical Oncology</i> , 2010 , 28, e701-3	2.2	8
24	Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 67, 348-54	5.9	17
23	Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 82-9	8.9	17
22	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1424-9	8.9	26
21	Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. <i>Medical Oncology</i> , 2010 , 27, 9-15	3.7	49
20	Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2010 , 11, 257-63	4.9	7
19	Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2010 , 126, 247-55	7.5	40
18	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. <i>Lung Cancer</i> , 2009 , 64, 346-51	5.9	40
17	Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. <i>Lung Cancer</i> , 2008 , 60, 92-97	5.9	10
16	First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 847-53	10.2	57
15	Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. <i>Clinical Cancer Research</i> , 2008 , 14, 162-8	12.9	118
14	Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. <i>Oncologist</i> , 2008 , 13, 1276-84	5.7	64
13	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2745-53	2.2	222
12	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. <i>Clinical Cancer Research</i> , 2008 , 14, 4877-82	12.9	242
11	Pleurocutaneous fistula after tube thoracostomy: sonographic findings. <i>Journal of Clinical Ultrasound</i> , 2008 , 36, 523-5	1	10

10	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20932-7	11.5	1395
9	The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. <i>Cancer Cell</i> , 2006 , 9, 209-23	24.3	273
8	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2006 , 118, 963-9	7.5	130
7	Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma. <i>Cancer Research</i> , 2006 , 66, 2553-61	10.1	57
6	EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 207-8	59.2	145
5	Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 8070-8	12.9	178
4	Collapsin response mediator protein-1: a novel invasion-suppressor gene. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 69-76	4.7	45
3	Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. <i>Lung Cancer</i> , 2001 , 34, 91-7	5.9	159
2	Elevated serum levels of mucin-associated antigen in patients with acute respiratory distress syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997 , 156, 1453-7	10.2	11
1	The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients. <i>Mindfulness</i> , 1	2.9	0